CommercialPrior AuthMedium impact
Dupixent (dupilumab)
Blue Cross & Blue Shield of Mississippi·MS · ENT (Ear, Nose & Throat), Gastroenterology, General Practice +3 more·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBS Mississippi has updated their prior authorization policy for Dupixent (dupilumab), a biologic medication used to treat multiple conditions including atopic dermatitis, asthma, COPD, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis. The policy establishes detailed criteria that must be met for each indication, including specific age requirements, disease severity measures, and documentation of failed conventional therapies.
Action Required
Immediately: Billing and prior authorization teams must review all pending and future Dupixent authorization requests to ensure they meet the updated criteria for each specific indication. Providers must document baseline symptom severity, evidence of failed conventional therapies within specified timeframes, and confirmation that patients will continue standard maintenance therapies. Update prior authorization checklists and EMR templates to include the specific criteria for each covered indication (atopic dermatitis, asthma, COPD, CRSwNP, eosinophilic esophagitis, prurigo nodularis).